Sponsor:
Kartos Therapeutics, Inc.
Code:
NCT04502394
Conditions
Diffuse Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
acalabrutinib
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations